Goldman Sachs maintained a Conviction Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $130.00. Comments follow ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Aegis Maintains Buy on Valeant (VRX); One-Time Items Don't Reflect True OperationsOctober 31, 2013 2:14 PM Valeant Pharmaceuticals International, Inc. (VRX) Reports Q3 EPS of $1.51October 31, 2013 6:52 AM